Literature DB >> 27276846

Glycated Haemoglobin and Diabetic Retinopathy in Type 2 Diabetic Patients in HRH Princess Maha Chakri Sirindhorn Medical Center.

Peerapat Tangjai, Preerati Chingchana, Rutchapom Taweerutchana.   

Abstract

OBJECTIVE: Diabetic retinopathy (DR) is an important cause of blindness in type 2 diabetic patients. When it occurs, it affects the patient's quality of life including their physical activity, emotion, mentality, and social interactions. Therefore, the objectives of this research were to study the relationship between glycaemic control and DR and the relationship between DR and other factors. We also aim to find the optimal cut-off point to screen diabetic retinopathy using glycated haemoglobin (HbA₁c) levels. MATERIAL AND
METHOD: We performed a case-control study. One hundred patients were divided into two groups (50 patients for DR group and 50 patients for non-DR group). Their HbA₁c, weight, height, blood pressure, and lipid profiles were retrospectively reviewed by Electronic Medical Record (EMR). The data was analysed using both Chi-square test and logistic regression with two-tailed hypothesis.
RESULTS: The research revealed that uncontrolled glycaemic in type 2 diabetic patients was significantly related to DR (Adjusted odds ratio 8.89, 95% CI = 2.3-18.00, p-value < 0.001). In addition, it occurred more commonly in males (Adjusted odds ratio 6.41, 95% CI = 3.02-26.25, p-value < 0.001). A cut-off level of HbA₁c for screening DR is 7.25% (sensitivity 84%, specificity 66%, positive predictive value = 71.2%, negative predictive value = 80.5%).
CONCLUSION: HbA₁c level and male gender are strongly related to DR (p < 0.001) and the optimal cut-off level for DR screening is 7.25% in type 2 diabetic patients that were treated in HRH Princess Maha Chakri Sirindhorn Medical Center.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 27276846

Source DB:  PubMed          Journal:  J Med Assoc Thai        ISSN: 0125-2208


  1 in total

1.  Efficacy and Safety of Intravitreal Conbercept, Ranibizumab, and Triamcinolone on 23-Gauge Vitrectomy for Patients with Proliferative Diabetic Retinopathy.

Authors:  Jinglin Cui; Hong Chen; Hang Lu; Fangtian Dong; Dongmei Wei; Yan Jiao; Steve Charles; Weikuan Gu; Lin Wang
Journal:  J Ophthalmol       Date:  2018-06-25       Impact factor: 1.909

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.